FCCC LOGO Faculty Publications
Pollyea DA , Bixby D , Perl A , Bhatt VR , Altman JK , Appelbaum FR , de Lima M , Fathi AT , Foran JM , Gojo I , Hall AC , Jacoby M , Lancet J , Mannis G , Marcucci G , Martin MG , Mims A , Neff J , Nejati R , Olin R , Percival ME , Prebet T , Przespolewski A , Rao D , Ravandi-Kashani F , Shami PJ , Stone RM , Strickland SA , Sweet K , Vachhani P , Wieduwilt M , Gregory KM , Ogba N , Tallman MS
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
J Natl Compr Canc Netw. 2021 Jan 6;19(1) :16-27
Back to previous list
Abstract
The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.
Notes
1540-1413 Pollyea, Daniel A Bixby, Dale Perl, Alexander Bhatt, Vijaya Raj Altman, Jessica K Appelbaum, Frederick R de Lima, Marcos Fathi, Amir T Foran, James M Gojo, Ivana Hall, Aric C Jacoby, Meagan Lancet, Jeffrey Mannis, Gabriel Marcucci, Guido Martin, Michael G Mims, Alice Neff, Jadee Nejati, Reza Olin, Rebecca Percival, Mary-Elizabeth Prebet, Thomas Przespolewski, Amanda Rao, Dinesh Ravandi-Kashani, Farhad Shami, Paul J Stone, Richard M Strickland, Stephen A Sweet, Kendra Vachhani, Pankit Wieduwilt, Matthew Gregory, Kristina M Ogba, Ndiya Tallman, Martin S Journal Article United States J Natl Compr Canc Netw. 2021 Jan 6;19(1):16-27. doi: 10.6004/jnccn.2021.0002.